<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658017</url>
  </required_header>
  <id_info>
    <org_study_id>700-00002</org_study_id>
    <nct_id>NCT04658017</nct_id>
  </id_info>
  <brief_title>GARNET™ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection</brief_title>
  <official_title>Feasibility of Hemodialysis With the GARNET Device in Chronic Hemodialysis Patients With a Bloodstream Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boa Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avania</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boa Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility of performing combined hemodialysis with the GARNET device in&#xD;
      chronic hemodialysis patients with a blood stream infection (BSI), and measure clinical&#xD;
      performance and safety endpoints.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center, single- arm study. Each subject will receive two (2)&#xD;
      sessions of hemodialysis with the GARNET each of 3-4 hour duration at a blood flow rate of&#xD;
      250 to 400 mL/min. Any necessary dialysis treatment dosing prescription changes will be made&#xD;
      by the treating physician, based on results of small molecule clearance (i.e., urea reduction&#xD;
      ratio (URR)). After the second treatment session with the GARNET device, the subjects will&#xD;
      resume their hemodialysis regimen using a standard hemodialyzer. Subjects will be followed&#xD;
      for 30 days after the final treatment session to evaluate safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All enrolled subjects will receive treatment with the GARNET device</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - Rate of adjudicated device- or GARNET device procedure-related Serious Adverse Events (SAEs)</measure>
    <time_frame>30-day follow-up post-2nd GARNET device treatment</time_frame>
    <description>Rate of adjudicated device or GARNET device procedure-related Serious Adverse Events (SAEs) All primary safety endpoints will be reported as adjudicated by the designated Clinical Events Committee (CEC) during treatment and through the 30-day follow-up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resolution of Blood Stream Infection at 30-days post 2nd GARNET device treatment</measure>
    <time_frame>30-day follow-up post-2nd GARNET device treatment</time_frame>
    <description>• Resolution of Blood Stream Infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance for small (blood urea nitrogen) and middle (beta-2-microglobulin) molecule solutes by the GARNET device, as measured by the intra-dialytic urea and beta-2-microglobulin reduction ratio.</measure>
    <time_frame>During Week 1 participation - Day 0: pre and post first GARNET device treatment and pre and post second GARNET device treatment which must occur by Day 7.</time_frame>
    <description>• Extent of clearance of solutes (small and middle molecules)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Bloodstream Infection</condition>
  <arm_group>
    <arm_group_label>GARNET device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All enrolled subjects will receive treatment with the GARNET device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GARNET device</intervention_name>
    <description>Use of new filter in conjunction with standard of care dialysis.</description>
    <arm_group_label>GARNET device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Hospitalized adults (age ≥ 18 years and ≤ 90 years)&#xD;
&#xD;
          2. Patients on chronic hemodialysis for ≥ 3 hours per treatment and a minimum of 3 times&#xD;
             per week schedule&#xD;
&#xD;
          3. Suspected or confirmed BSI as defined by:&#xD;
&#xD;
             a. For a suspected central-line (temporary or tunneled central venous catheters) and&#xD;
             non- central line (arterio-venous fistula and arterio-venous graft) vascular&#xD;
             infection:&#xD;
&#xD;
             i. presence of at least one of the following signs or symptoms:&#xD;
&#xD;
        1. fever (&gt;38.0°C), 2. pain*, 3. erythema*, or 4. heat at involved vascular site* (*with no&#xD;
        other recognized cause); or&#xD;
&#xD;
        ii. presence of purulent drainage/pus at the vascular site, in accordance with the CDC/NHSN&#xD;
        Surveillance Definitions for Specific Types of Infections&#xD;
&#xD;
        b. For other suspected infections:&#xD;
&#xD;
        i. presence of at least 2 of the 4 SIRS criteria:&#xD;
&#xD;
          1. Body temperature &gt; 101°F (38.3°C) or &lt; 96.8°F (36°C);&#xD;
&#xD;
          2. Heart rate &gt; 90 beats per minute;&#xD;
&#xD;
          3. Respiratory rate &gt; 20 breaths per minute;&#xD;
&#xD;
          4. White blood cell count &gt; 12,000/mm³, &lt; 4,000/mm³, or &gt; 10% bands&#xD;
&#xD;
             c. For confirmed infections:&#xD;
&#xD;
             i. laboratory-confirmed BSI based on the isolation of an organism from blood cultures;&#xD;
             or&#xD;
&#xD;
             ii. If a laboratory-confirmed BSI due to a commensal organism, the presence of at&#xD;
             least one of the following signs or symptoms will be required: fever (&gt;38.0˚C),&#xD;
             chills, or hypotension.&#xD;
&#xD;
        4. Subject agrees to comply with all follow-up evaluations&#xD;
&#xD;
        5. Subject has provided written informed consent; or if unable to perform informed consent,&#xD;
        written informed consent on behalf of the subject has been provided by a legally-authorized&#xD;
        representative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy confirmed by positive urine or serum test, or lactating mothers&#xD;
&#xD;
          2. Subject with severe concomitant disease expected to prolong hospitalization or cause&#xD;
             death in ≤ 30 days, or terminal illness, or &quot;do not resuscitate&quot; code status&#xD;
&#xD;
          3. Known sensitivity/allergy to heparin&#xD;
&#xD;
          4. Known sensitivity/allergy to polyethersulfone dialyzers&#xD;
&#xD;
          5. Active bleeding (e.g. active GI bleeding, hematuria or epistaxis, untreated&#xD;
             coagulopathy or bleeding from a non-compressible site)&#xD;
&#xD;
          6. Severe thrombocytopenia (platelet count &lt; 50,000/μL)&#xD;
&#xD;
          7. Active enrollment in another study (patients enrolled in an observational study&#xD;
             without any interventions or in post-market surveillance do not need to be excluded)&#xD;
&#xD;
          8. Inability to achieve vascular access blood flow rates of ≥250mL/min during the&#xD;
             previous dialysis treatment&#xD;
&#xD;
          9. Requirement for Continuous Renal Replacement Therapy/Sustained Low Efficiency Dialysis&#xD;
             (CRRT/SLED) due to hemodynamic instability&#xD;
&#xD;
         10. Hemodynamic instability&#xD;
&#xD;
         11. Medical conditions requiring regular blood transfusion&#xD;
&#xD;
         12. Hypocalcemia or clinical symptoms of hypocalcemia at time of enrollment&#xD;
&#xD;
         13. History of or known hypercoagulable state (e.g. Systemic Lupus Erythematosus (SLE),&#xD;
             antiphospholipid syndrome/lupus anticoagulant, protein C or S deficiency, antithrombin&#xD;
             deficiency, factor V Leiden deficiency, active cancer, sickle cell disease, and&#xD;
             history of deep vein thrombosis (DVT))&#xD;
&#xD;
         14. History of a condition documented in the medical record within 6 months prior to&#xD;
             enrollment that may result in an increased risk for thrombosis, including any of the&#xD;
             following:&#xD;
&#xD;
               1. Multiple incidents (≥ 2) of unresolvable thrombosis-induced catheter malfunctions&#xD;
                  which required catheter exchange, occurring within the 6 months prior to&#xD;
                  enrollment&#xD;
&#xD;
               2. Prior history of renal transplant thrombosis&#xD;
&#xD;
               3. Elevated Factor VIII with or without familial hypercholesterolemia&#xD;
&#xD;
               4. Hyperhomocysteinemia with a homocysteine level of &gt;4 mg/L (17.2 μmol/L)&#xD;
&#xD;
         15. Currently taking oral contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nisha V Varma</last_name>
    <phone>617-963-8990</phone>
    <phone_ext>6260</phone_ext>
    <email>nvarma@miraki.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>George Washington University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominic Raj, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominic Raj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Renu Regunathan-Shenk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Danielle Davison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland at Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew R Weir, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthew R Weir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neil Agarwal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Farhan Ali, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20889</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alon Dagan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alon Dagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akram Khan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Akram Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raghav Wusirika, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Horacio E Adrogue, MD, FASN</last_name>
    </contact>
    <investigator>
      <last_name>Horacio E Adrogue, MD, FASN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dialysis</keyword>
  <keyword>Blood Stream Infection</keyword>
  <keyword>Infection</keyword>
  <keyword>Bloodstream</keyword>
  <keyword>PAMPs</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be made available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

